“彻底失望”！德银首次下调诺和诺德评级

Group 1 - Novo Nordisk faced setbacks in key weight loss drug clinical trials, leading to a rare downgrade wave from Wall Street investment banks, with Deutsche Bank lowering the company's stock rating for the first time in five years [1] - The company's weight loss drug CagriSema is underperforming compared to major competitor Eli Lilly's similar product, prompting Deutsche Bank analyst Emmanuel Papadakis to downgrade the rating from "Buy" to "Hold" [1] - Following this news, Novo Nordisk's stock price plummeted 16% on Monday and continued to decline by 2% in early Copenhagen trading, raising investor concerns about the competitiveness of the company's core pipeline [1] Group 2 - Deutsche Bank analyst Emmanuel Papadakis also reduced the target price by 31%, indicating that the mid-term outlook for Novo Nordisk has been significantly impacted [2] - JPMorgan quickly followed suit, downgrading Novo Nordisk's rating from "Overweight" to "Neutral" and slashing sales forecasts for CagriSema by up to 63% for the years 2027 to 2030 [2] - The consensus among analysts has shifted significantly, with only 37% currently rating Novo Nordisk as "Buy," the lowest level since the end of 2021 [2] Group 3 - Despite the recent downgrades and stock price drop, Wall Street maintains some valuation space for Novo Nordisk, with the average target price still about 38% higher than the current trading price [3] - Attention may shift to other research pipelines within the company, particularly the drug ziltivekimab, which is highlighted by JPMorgan as a key catalyst outside the weight loss sector [3] Group 4 - The third-phase clinical data for ziltivekimab is expected to be released in the third quarter of this year, which could validate the drug's effectiveness in reducing cardiovascular event risks in patients with established atherosclerotic cardiovascular disease, chronic kidney disease, and systemic inflammation [4]